Alcon Laboratories, Inc.

Synthelabo

Louis M Desantis, Jr

Verney L Sallee

Michael A Kapin

Mark R Hellberg

Billie M York

Thomas R Dean

Salomon Z Langer

Bernard Scatton

Joseph M DeFaller

K Roger Aoki

Isoquinolinesulfonyl compounds are used in ophthalmic compositions to treat glaucoma or other ischemic-borne ocular disorders such as retinopathies or optic neuropathies. These compounds vasodilate ocular blood vessels, lower IOP and prevent or reduce the progression of visual field loss.

Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia

The present invention relates to the field of ophthalmology. In particular the invention relates to the field of ocular disorders including visual field loss and glaucoma using an isoquinolinesulfonyl compound, which lowers intraocular pressure (IOP) and produces dilation of ocular blood vessels.

The use of polyamine site antagonists in treating ischemic disorders of the retina and optic nerve head are disclosed. Especially preferred are certain 1-phenyl-2-piperidinoalkanol derivatives, such as eliprodil and ifenprodil.

Treatment of ischemic disorders of the retina and optic nerve head

Ophthalmic pharmaceutical compositions useful in controlling elevated intraocular pressure associated with glaucoma and ocular hypertension are described. The compositions comprise a combination of a beta-blocker and a carbonic anhydrase inhibitor to reduce the production of aqueous humor, preferably formulated as a suspension having a pH between about 6.8 and about 7.8. These compositions may additionally contain a mucomimetic anionic polymer and/or a finely-divided drug carrier substrate to provide sustained release. A method of controlling elevated intraocular pressure with these compositions is also described.

Topical anti-glaucoma compositions

Disclosed is the use of combinations of F and E series prostaglandins and their respective derivatives and analogues, as well as pharmaceutically acceptable salts and esters thereof in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising said combinations.

Prostaglandin combinations in glaucoma therapy

Ophthalmic pharmaceutical compositions useful in controlling elevated intraocular pressure associated with glaucoma and other ophthalmic conditions are described. A method of controlling elevated intraocular pressure with those compositions is also described. The compositions contain a combination of an alpha-2 agonist (e.g., para-amino clonidine) and a beta blocker (e.g., betaxolol).

Use of a combination of apraclonidine and timolol to control intraocular

Disclosed are methods of using certain defined phenylene dioxamic acids in treating allergic ocular responses, such as, hayfever, conjunctivitis, atopic and keratoconjunctivitis, vernal conjunctivitis, giant capillary conjunctivitis and other diseases where mast cell degranulation are important in the etiology, by topical administration of said active to the affected eye; also disclosed are pharmaceutical compositions comprising said actives.

Use of lodoxamide to treat ophthalmic allergic conditions

Disclosed is the use of Tri-methyl PG-F.sub.2 a, and its derivatives, such as, 15-acetyl Tri-methyl PG-F.sub.2 a and pharmaceutically acceptable esters thereof in the treatment of glaucoma and intraocular hypertension. Also disclosed are ophthalmic pharmaceutical compositions comprising Tri-methyl PG-F.sub.2 a and its derivatives.

Use of tri-methyl PG-F.sub.2 a and derivatives in glaucoma therapy

Disclosed is the use of trimoprostil, and its derivatives, such as, 15-acetyl trimoprostil and pharmaceutically acceptable salts and esters thereof in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising trimoprostil and its derivatives.

Use of trimoprostil and derivatives in glaucoma therapy

A method of controlling anterior segment ocular bleeding is described. The method utilizes various clonidine derivatives (e.g., p-aminoclonidine) as the hemostatic agent.

Growing community of inventors

Fort Worth, TX, United States of America

Louis M Desantis, Jr